Kelderman added, "Our differentiated portfolio of advanced life science tools, reagents, and diagnostic products continues to enable breakthroughs in science and medicine. With our world-class team, sharpened strategic focus, innovation capabilities and sector-leading financial profile, Bio-Techne remains well positioned to deliver long-term value for all stakeholders." Conference Call Bio-Techne will host an earnings conference call today, November 5, 2025 at 8:00 a.m. CST. To listen, please dial 1-800-274 ...

Core Insights - Bio-Techne Corporation reported a 1% decrease in net sales for the first quarter of fiscal 2026, totaling $286.6 million, with organic revenue also down by 1% compared to the previous year [6][9][30] - The company experienced a 19% increase in GAAP operating income, reaching $47.7 million, and a GAAP EPS of $0.24, up from $0.21 in the same quarter last year [7][21] - Adjusted operating margin improved to 29.9%, reflecting ongoing productivity and cost containment initiatives [10][24] Financial Performance - Net sales decreased by 1% to $286.6 million, with organic revenue also down by 1%, influenced by a favorable foreign currency impact of 1% and an unfavorable impact from businesses held-for-sale [6][9] - GAAP operating income increased by 19% to $47.7 million, with an operating margin of 16.6%, up from 13.8% in the prior year [7][24] - Adjusted EPS remained stable at $0.42, while adjusted operating income rose to $84.2 million from $83.2 million [10][28] Segment Performance - The Protein Sciences segment reported net sales of $202.2 million, a decrease of 1% from $204.5 million in the prior year, with an operating margin of 38.4% [12][29] - The Diagnostics and Spatial Biology segment saw net sales of $79.5 million, down 4% from $83.2 million, but achieved organic revenue growth of 3% [13][29] - The overall operating income for the segments combined was $86.6 million, with a notable increase in the operating margin for the Diagnostics and Spatial Biology segment to 11.2% from 5.1% [31] Strategic Initiatives - The company completed the divestiture of its Exosome Diagnostics business to focus on non-CLIA based product lines, aligning with its growth strategy [9][10] - Bio-Techne's leadership expressed optimism regarding the stabilization of the US academic end market and continued strength from large pharmaceutical customers [3][9] - The company is positioned to leverage its differentiated portfolio of advanced life science tools and reagents to drive long-term value [3][10]

Core Insights - Bio-Techne Corporation and Nucleai presented pivotal data from the SECOMBIT clinical trial at the SITC 2025 Annual Meeting, highlighting the importance of spatial biology in immuno-oncology research [1][2] Study Overview - The SECOMBIT trial combined an immuno-oncology multiplex immunofluorescence panel with AI-driven multimodal biomarker analysis, profiling 42 pre-treatment biopsies from metastatic melanoma patients [2][5] - The study utilized Bio-Techne's COMET platform and Nucleai's multimodal spatial operating system to correlate immune cell interactions with clinical outcomes such as progression-free survival (PFS) and overall survival (OS) [2][5] Key Findings - The location and interaction of immune cells within tumors significantly influence treatment success, enabling better predictions of patient responses to therapies [4] - Specific immune activation markers were linked to improved outcomes across different treatment arms, indicating the potential of spatial biomarkers in clinical decision-making [6][4] Clinical Trial Data - The trial data demonstrated that Bio-Techne's and Nucleai's technologies can identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapy [5] - The study was recognized as one of the top 150 abstracts from over 1,200 submissions at the SITC 2025 [5] Availability at SITC 2025 - Bio-Techne's spatial biology portfolio, including the new ProximityScope assay, will be showcased at Booth 603, with visual data from the SECOMBIT study presented in Poster 528 [7] Company Background - Bio-Techne Corporation is a global life sciences company with over $1.2 billion in net sales for fiscal 2025, providing tools and reagents for research and clinical diagnostics [8] - Nucleai specializes in AI-powered multimodal spatial biology, integrating high-plex spatial proteomics and clinical data to develop precision medicine products [9]

Bio-Techne (NasdaqGS:TECH) FY 2025 Annual General Meeting October 30, 2025 09:00 AM ET Company ParticipantsShane Bohnen - General Counsel and Corporate SecretaryOperatorGood morning and welcome to the Bio-Techne Corporation Annual Meeting of Shareholders. I would now like to turn the conference call over to Shane Bohnen, General Counsel and Corporate Secretary of Bio-Techne. Please go ahead.Shane BohnenWelcome to our annual shareholders meeting. It is 8:00 A.M. Central Time on October 30th, 2025, and the me ...

Bio-Techne (NasdaqGS:TECH) FY 2025 Annual General Meeting October 30, 2025 09:00 AM ET Speaker0Good morning and welcome to the Bio-Techne Corporation Annual Meeting of Shareholders. I would now like to turn the conference call over to Shane Boonen, General Counsel and Corporate Secretary of Bio-Techne. Please go ahead. Welcome to our annual shareholders meeting. It is 8:00 A.M. Central Time on October 30, 2025, and the meeting is called to order. Today's meeting will be limited to the business matters outli ...

Core Insights - Bio-Techne Corporation has launched the ProximityScope assay, a spatial solution that integrates with the BOND RX staining platform from Leica Biosystems, enabling visualization of functional protein-protein interactions on fixed tissue with subcellular resolution [1][2][4] Product Features - The ProximityScope assay provides a visual signal only when two proteins are in close proximity, offering insights into biological mechanisms that were previously inaccessible [2] - It works in conjunction with the BOND RX staining system and ACD's RNAscope Multiomic LS kit, allowing for enhanced detection of RNA and protein on the same tissue section [2] - The assay combines high sensitivity, specificity, and low background, addressing limitations of traditional methods like bulk pull-down assays [3] Applications - Key applications include visualizing cell-cell interactions for immune checkpoint studies, analyzing cell surface interactions that activate signaling pathways, evaluating antibody-based therapeutics, and investigating intracellular interactions related to transcriptional activation [4] Industry Context - The ProximityScope assay represents a significant advancement in spatial biology, providing researchers with a powerful automated solution to decode complex biological systems and accelerate therapeutic innovation [3][4] - Bio-Techne generated over $1.2 billion in net sales in fiscal 2025, indicating strong market presence and demand for innovative life science tools [6]

Core Insights - Bio-Techne Corporation (TECH) is scheduled to release its first-quarter fiscal 2026 results on November 5, before market opening [1] - The company reported adjusted earnings per share (EPS) of 53 cents in the last quarter, exceeding the Zacks Consensus Estimate by 6.00%, with an average surprise of 9.22% over the last four quarters [1] Q1 Estimates for TECH - The Zacks Consensus Estimate for revenues is $289.3 million, reflecting a slight decrease of 0.04% from the previous year [2] - EPS is expected to remain flat at 42 cents year-over-year [2] Estimate Revision Trend - Earnings estimates have remained constant at 42 cents over the past 30 days [3] Factors Affecting Performance - Management indicated that macro uncertainties, including tariffs and potential NIH budget cuts, could slow growth momentum in Q1 fiscal 2026 [4] - The Protein Sciences division, which accounted for 72.5% of net sales in fiscal 2025, is expected to drive revenues through proteomic analytical tools and cell therapy workflow solutions [5] Product Portfolio and Growth - The core portfolio includes over 6,000 proteomic agents and 400,000 antibody types, supporting global customers in advancing therapeutics for precision diagnostics [6] - The protein analytical instrumentation business is anticipated to show strong momentum, continuing a trend of mid-teens year-over-year growth in instrument placements [7] - Demand for the next-generation high-throughput instrument, Leo, is expected to remain strong [8] Strategic Developments - A strategic distribution partnership with Sphere Bio will allow Bio-Techne to distribute ultrasensitive immunoassays for Alzheimer's disease biomarkers, potentially impacting Q1 revenues [9] Segment Performance - Protein Sciences revenues may rise due to strength in proteomic tools and cell therapy workflows, while Spatial Biology sales are likely to decline due to NIH funding concerns and project timing [10] - The consensus estimate for Spatial Biology revenues is $80.7 million, down 3% from the previous year [14] Challenges in Diagnostics and Spatial Biology - Organic revenues in the Diagnostics and Spatial Biology segment may have declined due to order timing and macro uncertainties affecting growth in the ExoDx prostate cancer test and diagnostic reagents business [12] - The Spatial Biology segment is facing headwinds from NIH funding uncertainty and a weaker biotech funding environment [13] Company Outlook - Bio-Techne has an Earnings ESP of -4.19%, indicating a lower chance of beating estimates [15] - The company currently holds a Zacks Rank of 3 (Hold) [16]

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has awarded four G-Rex Grants totaling $375,000 to faculty members at Children's National Hospital to support cell and gene therapy initiatives [1][7]. Grant Details - Dr. Patrick Hanley received a $100,000 G-Rex Grant to develop a cost-effective CAR-T cell manufacturing process [2]. - Dr. Michael Keller and Dr. Hanley were awarded a $150,000 G-Rex Grant for optimizing Virus Specific T cell and Tumor Antigen Associate T cell manufacturing processes using G-Rex "M" series bioreactors [3]. - Dr. Amy Hont received a $75,000 G-Rex Grant for developing a closed system G-Rex manufacturing process for ATTACK TAAT cell therapy [4]. - Dr. Conrad Russell Cruz was awarded a $50,000 G-Rex Grant for optimizing CAR-modified TAAT cell manufacturing [4]. Program Impact - ScaleReady's G-Rex Grant Program has surpassed $40 million in no-cost product commitments aimed at advancing cell and gene-modified cell therapy development [7]. - Individual grants can be worth up to $300,000, and recipients gain access to exclusive support from ScaleReady's consortium of partners [7]. New Initiatives - ScaleReady has launched a free program called LEAN Cell & Gene™ in partnership with Hanson Wade to enhance CGT manufacturing efficiency [8]. Industry Context - Children's National Hospital is recognized as a leader in pediatric cell and gene-modified therapies, emphasizing the importance of collaboration in advancing these therapies [5][6]. - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials [10].

Company Overview - Bio-Techne Corporation (TECH) is headquartered in Minneapolis, Minnesota, and specializes in developing, manufacturing, and selling life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets, with a market cap of $9.3 billion [1] Earnings Expectations - Analysts expect TECH to report a profit of $0.37 per share on a diluted basis for the fiscal first quarter of 2026, which is unchanged from the same quarter last year [2] - For the full fiscal year, analysts project an EPS of $1.76, reflecting a 2.9% increase from $1.71 in fiscal 2025, and an expected rise to $2 in fiscal 2027, representing a 13.6% year-over-year growth [3] Stock Performance - TECH stock has underperformed the S&P 500 Index, which gained 14.4% over the past 52 weeks, with TECH shares down 18.7% during the same period [4] - The stock also underperformed the Health Care Select Sector SPDR Fund, which saw a 7.8% loss in the same timeframe [4] Recent Financial Results - On August 6, TECH reported its Q4 results, with an adjusted EPS of $0.53, surpassing Wall Street expectations of $0.50, and revenue of $317 million, exceeding forecasts of $315.4 million [5] Analyst Ratings - The consensus opinion on TECH stock is bullish, with a "Strong Buy" rating overall; out of 16 analysts, 11 recommend "Strong Buy," one suggests "Moderate Buy," and four give a "Hold" rating [6] - The average analyst price target for TECH is $66.77, indicating a potential upside of 11.9% from current levels [6]

Core Insights - Bio-Techne (TECH) is expanding its portfolio through acquisitions and strategic investments, indicating strong growth potential, particularly in international markets [1][8] - The company has experienced a decline in share price by 20.3% over the past year, contrasting with a 5.8% decline in the industry and an 18.7% rise in the S&P 500 [2] - Bio-Techne's market capitalization stands at $9.64 billion, with earnings consistently surpassing estimates in the last four quarters, averaging a surprise of 9.2% [2] Expansion and Growth Strategies - In fiscal 2024, Bio-Techne completed the acquisition of Lunaphore, which achieved nearly 50% growth for the full year despite order timing delays [3] - The company holds a 20% stake in Wilson Wolf, which is expected to grow by more than 20% in fiscal 2025, maintaining EBITDA margins above 70% [3] - Bio-Techne introduced ProPak GMP Cytokines to support CAR-T and TCR-T manufacturing workflows, reinforcing its leadership in RUO assays through a partnership with Sphere Bio [4] International Market Performance - Bio-Techne's core portfolio includes over 6,000 protein and 400,000 antibody types, essential for life science research globally [5] - In the fiscal fourth quarter, sales in the Americas grew in the low single digits, while Europe saw mid-single-digit growth driven by biopharma demand [5] - The Asia-Pacific region, excluding China, experienced low single-digit growth, with China showing low double-digit growth due to improved demand [6] Financial Health - As of June 30, 2025, Bio-Techne's total debt was $346 million, with cash and cash equivalents at $162 million, indicating a stable liquidity position [9] - Despite higher quarterly debt compared to cash levels, the company had no short-term payable debt on its balance sheet [9] Challenges and Competitive Landscape - The macroeconomic environment has led to increased raw material and labor costs, impacting the company's operations and margins [10] - Bio-Techne faces intense competition from both large global companies and smaller niche competitors, leading to pricing pressures [11] - The company's cost of sales rose by 15% in the fourth quarter of fiscal 2025, with selling, general, and administrative expenses increasing by 47.2% year over year [10] Earnings Estimates - The Zacks Consensus Estimate for Bio-Techne's fiscal 2026 earnings remains at $2.00, with revenues projected at $1.24 billion, reflecting a 1.7% increase from the previous year [12]